135 related articles for article (PubMed ID: 38462352)
21. Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia.
Wang Y; Zhou R; Wang H; Liu H; Wang J
Int J Gynecol Cancer; 2019 May; 29(4):699-704. PubMed ID: 30826750
[TBL] [Abstract][Full Text] [Related]
22. The role of prolonged progestin treatment and factors predicting successful fertility-sparing treatment for early endometrial endometrioid adenocarcinoma.
Ou YC; Fu HC; Lan J; Wu CH; Kung FT; Lan KC; Tsai YC; Lin H
Eur J Obstet Gynecol Reprod Biol; 2021 Dec; 267():99-104. PubMed ID: 34739876
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.
Zhou R; Yang Y; Lu Q; Wang J; Miao Y; Wang S; Wang Z; Zhao C; Wei L
Gynecol Oncol; 2015 Dec; 139(3):424-8. PubMed ID: 26428941
[TBL] [Abstract][Full Text] [Related]
24. Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients.
Yang B; Xie L; Zhang H; Zhu Q; Du Y; Luo X; Chen X
J Gynecol Oncol; 2018 May; 29(3):e35. PubMed ID: 29533020
[TBL] [Abstract][Full Text] [Related]
25. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
[TBL] [Abstract][Full Text] [Related]
26. Fertility-Sparing Treatment in Young Women with Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer: A Tertiary Center Experience.
Shikeli S; Gowri V; Rawahi TA
JBRA Assist Reprod; 2020 Oct; 24(4):466-469. PubMed ID: 32569453
[TBL] [Abstract][Full Text] [Related]
27. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis.
Chae-Kim J; Garg G; Gavrilova-Jordan L; Blake LE; Kim TT; Wu Q; Hayslip CC
Int J Gynecol Cancer; 2021 Dec; 31(12):1499-1505. PubMed ID: 34785524
[TBL] [Abstract][Full Text] [Related]
29. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
Gong Q; Chen X; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
[TBL] [Abstract][Full Text] [Related]
30. Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome.
Wang L; Luo X; Wang Q; Lv Q; Wu P; Liu W; Chen X
J Gynecol Oncol; 2021 Sep; 32(5):e70. PubMed ID: 34132069
[TBL] [Abstract][Full Text] [Related]
31. [Clinical analysis of fertility-sparing therapy of patients with complex atypical hyperplasia and endometrial cancer].
Morimoto C; Wang YQ; Zhou R; Wang JL
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):936-942. PubMed ID: 36241236
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and pregnancy outcomes of hysteroscopic surgery combined with progestin as fertility-sparing therapy in patients with early stage endometrial cancer and atypical hyperplasia.
Xi Y; Liu G; Liu D; Jiang J; Gong R
Arch Gynecol Obstet; 2023 Feb; 307(2):583-590. PubMed ID: 35674831
[TBL] [Abstract][Full Text] [Related]
33. Conservative management of grade 2 stage IA endometrial carcinoma and literature review.
Shan W; Wu P; Yang B; Zhang H; Sun L; Lv Q; Luo X; Cheng Y; Zhu Q; Chen X
J Obstet Gynaecol Res; 2021 Mar; 47(3):984-991. PubMed ID: 33403812
[TBL] [Abstract][Full Text] [Related]
34. Continued medical treatment for persistent early endometrial cancer in young women.
Cho A; Lee SW; Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT
Gynecol Oncol; 2021 Feb; 160(2):413-417. PubMed ID: 33246662
[TBL] [Abstract][Full Text] [Related]
35. The pregnancy and oncology outcome of fertility-sparing management for synchronous primary neoplasm of endometrium and ovary.
Gama Q; Luo S; Wu P; Wang L; Liu S; Zhang H; Sun L; Wang Y; Yu M; Chen X; Shan W; Luo X
J Ovarian Res; 2023 Dec; 16(1):235. PubMed ID: 38062462
[TBL] [Abstract][Full Text] [Related]
36. Fertility-sparing management for endometrial cancer: review of the literature.
Garzon S; Uccella S; Zorzato PC; Bosco M; Franchi MP; Student V; Mariani A
Minerva Med; 2021 Feb; 112(1):55-69. PubMed ID: 33205638
[TBL] [Abstract][Full Text] [Related]
37. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002).
Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Seong SJ; Kim TJ; Kim JW; Kim SM; Bae DS; Nam JH
Eur J Cancer; 2013 Mar; 49(4):868-74. PubMed ID: 23072814
[TBL] [Abstract][Full Text] [Related]
38. Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience.
Wang Y; Yu M; Yang JX; Cao DY; Yuan Z; Zhou HM; Zhang Y; Li L; Shen K; Wu H
Int J Clin Oncol; 2019 Jun; 24(6):712-720. PubMed ID: 30746595
[TBL] [Abstract][Full Text] [Related]
39. [Analysis of prognosis and pregnancy outcomes of fertility-preserving treatment for patients with stage Ⅰa, grade 2 endometrial cancer].
Wang YQ; Zhou R; Xu LJ; Xia M; Lu Q; Liu GL; Shen DH; Wang G; He M; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2020 May; 55(5):327-332. PubMed ID: 32464721
[No Abstract] [Full Text] [Related]
40. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]